Fundraising Fox

Renovion

Durham, US · Founded 2013 · North Carolina corporation · 1 known investors

BiotechHealthtechMedical Devices

Founders & leadership

DW
Daniel W. CopelandExecutive

Board

RF
R. Frederick McCoy, Jr.Board director
JD
Joseph DavisBoard director
DW
Derek WinstanlyBoard director

Investors · 1

Texas HALO FundHouston

Reported raises · per SEC filings

Form D private placements

$25.8M disclosed across 5 rounds · 2016–2022

▶$15MraisedMar 2023 · 24 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • THOMAS U. BARTONDirector
  • DEREK WINSTANLYDirector
  • RICHARD MATTINGLYDirector
  • DANIEL W. COPELANDExecutive Officer, Director
  • JON CIVITARESEDirector
Offering amount
$15M
Amount sold
$15M
First sale
Dec 2022
Incorporated
Corporation, North Carolina
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8.1MraisedMay 2020 · 43 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • THOMAS U. BARTONDirector
  • DEREK WINSTANLYDirector
  • DANIEL W. COPELANDExecutive Officer, Director
Offering amount
$8.1M
Amount sold
$8.1M
First sale
Feb 2020
Incorporated
Corporation, North Carolina
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$492.2KraisedFeb 2019 · 10 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • R. FREDERICK MCCOY, JR.Director
  • DANIEL W. COPELANDExecutive Officer, Director
  • DEREK WINSTANLYDirector
  • ROBERT RYANDirector
Offering amount
$800K
Amount sold
$492.2K
First sale
Jan 2019
Incorporated
Corporation, North Carolina
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$350KraisedMay 2018 · 12 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert RyanDirector
  • Daniel W. CopelandExecutive Officer, Director
  • R. Frederick McCoy, Jr.Director
  • Derek WinstanlyDirector
Offering amount
$350K
Amount sold
$350K
First sale
May 2018
Incorporated
Corporation, North Carolina, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.9MraisedJan 2017 · 13 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • R. Frederick McCoy, Jr.Director
  • Joseph DavisDirector
  • Derek WinstanlyDirector
  • Daniel W. CopelandExecutive Officer, Director
Offering amount
$2.1M
Amount sold
$1.9M
First sale
Aug 2016
Incorporated
Corporation, North Carolina, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Regeneron NASDAQ: REGN www.regeneron.com9 shared keywordsRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.

Companies competing with Renovion for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

Who are Renovion's investors?
Renovion's investors include Texas HALO Fund.
How much funding has Renovion raised?
Renovion has disclosed $25.8M raised across 5 rounds.
Where is Renovion headquartered?
Renovion is headquartered in Durham, US.